Carla Sans-Pola

Dr. Carla Sans-Pola

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2023 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
JCJúlia Corominas
Júlia Corominas
CGCarme Garriga
Carme Garriga
APAntoni Prenafeta
Antoni Prenafeta
AMAlexandra Moros
Alexandra Moros
MCManuel Cañete
Manuel Cañete
LFLaura Ferrer
Laura Ferrer
A SARS-CoV-2 protein-based heterodimer vaccine, PHH-1V, has been shown to be safe and well-tolerated in healthy young adults in a first-in-human, Phase I/IIa study dose-escalation trial. Here, we report the interim results of the Phase IIb HH-2, where the immunogenicity and safety of a heterologous booster with PHH-1V is assessed versus a homologous booster with BNT162b2 at 14, 28 and 98 days after vaccine administration. The HH-2 study is an ongoing multicentre, randomised, active-controlled, double-blind, non-inferiority Phase IIb trial, where participants 18 years or older who had received two doses of BNT162b2 were randomly assigned in a 2:1 ratio to receive a booster dose of vaccine —either heterologous (PHH-1V group) or homologous (BNT162b2 group)—in 10 centres in Spain. Eligible subjects were allocated to treatment stratified by age group (18–64 versus ≥65 years) with approximately 10% of the sample enrolled in the older age group. The primary endpoints were humoral immunogenicity measured by changes in levels of neutralizing antibodies (PBNA) against the ancestral Wuhan-Hu-1 strain after the PHH-1V or the BNT162b2 boost, and the safety and tolerability of PHH-1V as a boost. The secondary endpoints were to compare changes in levels of neutralizing antibodies against different variants of SARS-CoV-2 and the T-cell responses towards the SARS-CoV-2 spike glycoprotein peptides. The exploratory endpoint was to assess the number of subjects with SARS-CoV-2 infections ≥14 days after PHH-1V booster. This study is ongoing and is registered with ClinicalTrials.gov, NCT05142553. From 15 November 2021, 782 adults were randomly assigned to PHH-1V (n = 522) or BNT162b2 (n = 260) boost vaccine groups. The geometric mean titre (GMT) ratio of neutralizing antibodies on days 14, 28 and 98, shown as BNT162b2 active control versus PHH-1V, was, respectively, 1.68 (p < 0.0001), 1.31 (p = 0.0007) and 0.86 (p = 0.40) for the ancestral Wuhan-Hu-1 strain; 0.62 (p < 0.0001), 0.65 (p < 0.0001) and 0.56 (p = 0.003) for the Beta variant; 1.01 (p = 0.92), 0.88 (p = 0.11) and 0.52 (p = 0.0003) for the Delta variant; and 0.59 (p ≤ 0.0001), 0.66 (p < 0.0001) and 0.57 (p = 0.0028) for the Omicron BA.1 variant. Additionally, PHH-1V as a booster dose induced a significant increase of CD4+ and CD8+ T-cells expressing IFN-γ on day 14. There were 458 participants who experienced at least one adverse event (89.3%) in the PHH-1V and 238 (94.4%) in the BNT162b2 group. The most frequent adverse events were injection site pain (79.7% and 89.3%), fatigue (27.5% and 42.1%) and headache (31.2 and 40.1%) for the PHH-1V and the BNT162b2 groups, respectively. A total of 52 COVID-19 cases occurred from day 14 post-vaccination (10.14%) for the PHH-1V group and 30 (11.90%) for the BNT162b2 group (p = 0.45), and none of the subjects developed severe COVID-19. Our interim results from the Phase IIb HH-2 trial show that PHH-1V as a heterologous booster vaccine, when compared to BNT162b2, although it does not reach a non-inferior neutralizing antibody response against the Wuhan-Hu-1 strain at days 14 and 28 after vaccination, it does so at day 98. PHH-1V as a heterologous booster elicits a superior neutralizing antibody response against the previous circulating Beta and the currently circulating Omicron BA.1 SARS-CoV-2 variants in all time points assessed, and for the Delta variant on day 98 as well. Moreover, the PHH-1V boost also induces a strong and balanced T-cell response. Concerning the safety profile, subjects in the PHH-1V group report significantly fewer adverse events than those in the BNT162b2 group, most of mild intensity, and both vaccine groups present comparable COVID-19 breakthrough cases, none of them severe. HIPRA SCIENTIFIC, S.L.U.

7 July 2021 in Clinical Drug Investigation
Verified
Journal Article
Closed access
PDF file
EJEmilie Jouanjus
Emilie Jouanjus
CSCarla Sans-Pola
Carla Sans-Pola
BMBeatrice Mainoli
Beatrice Mainoli
FJFarideh Javid
Farideh Javid
IEIsabella Ekheden
Isabella Ekheden
VLVincent Leclerc
Vincent Leclerc

26 October 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CSCarla Sans-Pola
Carla Sans-Pola
AAAntònia Agustí
Antònia Agustí
JBJosep Àngel Bosch
Josep Àngel Bosch
IAIRENE AGRAZ
IRENE AGRAZ
CACarmen Alerany
Carmen Alerany
IDImmaculada Danés
Immaculada Danés
Off-label use of rituximab is commonly requested for patients with resistant nephropathies. The outcomes and tolerability of rituximab in adult patients with nephropathy treated at our hospital (from 2013 to 2018) were described. Data were retrieved from electronic medical records. Response was classified as complete remission (CR), partial remission (PR), or no response (NR) according to the KDIGO criteria. A total of 89 requests were received for 61 patients. Median age was 58 years (45.9% female). Idiopathic membranous nephropathy (MN) (n = 30) was the most frequent indication, followed by minimal change disease (MCD) (n = 15) and secondary membranoproliferative glomerulonephritis (MPGN) (n = 12). Three patients with focal segmental glomerulosclerosis (FSGS) were included. After most treatment cycles in MN, a CR or PR was observed; median proteinuria levels significantly decreased for these patients (6000 mg/24h (IQR 3584–10,300) vs. 1468.8 (IQR 500–4604.25), p < 0.01). In MPGN, no response was documented after 46.7% of rituximab cycles. A CR or PR was described with the majority of rituximab cycles in MCD, with a significant decrease in proteinuria (6000 mg/24 h (IQR 4007–11,426) vs. 196.8 (IQR 100–1300), p = 0.013). No cycles produced a response in FSGS. Mean CD19+ B-cell decreased in all types of nephropathy (10.44% vs. 0.29%, p < 0.0001). Eleven patients presented infusion-related reactions, and 17 presented infectious complications. The majority of patients with MN and MCD had complete or partial responses; however, neither MPGN nor FSGS had encouraging results.

31 January 2024
Verified
Preprint
Open access
JRJudit Riera-Arnau
Judit Riera-Arnau
EBElena Guillén Benítez
Elena Guillén Benítez
CSCarla Sans-Pola
Carla Sans-Pola
EZEsperanza Zuriguel-Pérez
Esperanza Zuriguel-Pérez
LLLina María Leguízamo-Martínez
Lina María Leguízamo-Martínez
EFEsther Cucurull Folguera
Esther Cucurull Folguera
Background: The COVID-19 pandemic led to an increase in research activity worldwide. The Vall d’Hebron University Hospital Research Ethics Committee (VH-REC) adapted its procedures to give out the opinion rapidly. We aimed to describe the characteristics of the VH-REC activity and studies evaluated during the first outbreak. Methods: Clinical trials (CT), post-authorization studies (PAS) and research projects (RP) on COVID-19 were included and followed up. Variables were described through usual descriptive methods. Results: 157 studies were evaluated: 10 CT, 16 PAS and 131 RP, in 25 bi-weekly online meetings. Non-commercial, unicentric and national studies predominated (95%, 54% and 88%, respectively). The main objective of CT and PAS studies was to test efficacy and safety, and for RP to describe patients’ outcomes. Some studies focused on specific interest groups, such as healthcare professionals or immunosuppressed patients (10% both). The median time of protocols’ evaluation was 3 days. 58.6% (92) required further clarifications, mainly due to aspects of data protection, informed consent, and biological samples. The final opinion was favourable in 93% (146). Regarding follow-up, 123 studies had been initiated and 64 also finalized. Results have been published in 59% (51) of studies. Conclusions and implications: COVID-19 pandemic has led to greater academic and local research, especially through research projects. Electronic sources were implemented for evaluation shortening and ease follow-up. These measures should remain to streamline VH-REC processes, and trends to publish results favoured. This study could allow comparisons with other activity periods (e.g. pre or post-pandemic), or with other REC’

6 November 2026 in Journal of Cancer Policy
Verified
Journal Article
Open access
GPG. Puig
G. Puig
IDImmaculada Danés
Immaculada Danés
CSCarla Sans-Pola
Carla Sans-Pola
AFAntonio Vallano Ferraz
Antonio Vallano Ferraz